At the news
? BULLISHIMPACT 6/10 8-K filed Nov 2, 2026 at 07:15 ET
Inovio Pharmaceuticals announced FDA accelerated approval of VOCERYQ (INO-3107), the first U.S. FDA-approved DNA medicine, to reduce surgery frequency in adults with Recurrent Respiratory Papillomatosis (RRP). The approval is based on a 32-patient Phase 1/2 study where 27% of evaluable patients required no surgical intervention for 12 months post-treatment. The company expects to begin shipping in approximately 60 days with full commercial launch in Q1 2027, but continued approval is contingent on a confirmatory study with a protocol due by end of 2026.
- FDA granted accelerated approval for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) to reduce the frequency of surgery in adults with RRP.
- Approval based on a Phase 1/2 study (RRP-001) in 32 patients; 26 patients in the efficacy population had a median of 4.5 surgeries in the 12 months prior to treatment.
- 7 out of 26 patients (27%, 95% CI: 12-48%) demonstrated a complete response, defined as no surgical excision of papillomas after 12 months of follow-up.
- VOCERYQ is the first U.S. FDA-approved DNA medicine, validating Inovio's platform technology.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access